Emisphere gets new patent for eligen technology for pulmonary care

By Elaine Rigoli

Tampa, Fla., April 12 - The U.S. Patent and Trademark Office has granted an additional patent to Emisphere Technologies, Inc. for the pulmonary delivery of proteins using Emisphere's eligen technology.

Emisphere received U.S. Patent number 6,991,798 with claims directed to the pulmonary delivery of peptides, according to a news release.

In addition, foreign patent number 2001273153, granted in March, provides Emisphere with additional patent protection for pulmonary delivery of peptides.

Three patents have been granted to Emisphere in 2006 containing language and/or claims affording patent protection for the pulmonary delivery of proteins, bringing the total of U.S. patents owned by Emisphere to nine, with additional applications concerning pulmonary routes of administration in progress, the release said.

The company also announced that it has generated promising preclinical data from studies conducted by Emisphere and its academic collaborators demonstrating that the bioavailability of insulin via pulmonary delivery with an eligen carrier was approximately two-fold higher than pulmonary dosing of insulin alone, and had a bioavailability greater than 70% when compared to subcutaneous dosing.

Emisphere is a biopharmaceutical company based in Tarrytown, N.Y.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.